Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bos

Showing results (751-760 of 777) with videos related to

Pageof 78
Sort By:
Critical Care Medicine|October 10, 2017
Respiratory Viruses in Invasively Ventilated Critically Ill Patients-A Prospective Multicenter Observational StudyFrank van Someren Gréve, Nicole P Juffermans, Lieuwe D J Bos, et al.
Nature Reviews. Nephrology|September 24, 2025
The immunology of sepsis: translating new insights into clinical practiceMatthijs Kox, Michael Bauer, Lieuwe D J Bos, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Journal of Clinical Immunology|May 20, 2023
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 PneumoniaQuentin Philippot, Arnaud Fekkar, Adrian Gervais, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Circulation|November 11, 2016
Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective StudiesBakhtawar K Mahmoodi, Mary Cushman, Inger Anne Næss, et al.
Hypertension (Dallas, Tex. : 1979)|January 28, 2020
Influence of Age on Upper Arm Cuff Blood Pressure MeasurementDean S Picone, Martin G Schultz, Petr Otahal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Pageof 78

Showing results (751-760 of 777) with videos related to

Sort By:
Pageof 78
Critical Care Medicine|October 10, 2017
Respiratory Viruses in Invasively Ventilated Critically Ill Patients-A Prospective Multicenter Observational StudyFrank van Someren Gréve, Nicole P Juffermans, Lieuwe D J Bos, et al.
Nature Reviews. Nephrology|September 24, 2025
The immunology of sepsis: translating new insights into clinical practiceMatthijs Kox, Michael Bauer, Lieuwe D J Bos, et al.
Oncotarget|October 20, 2018
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Chad C Bjorklund, et al.
Blood|September 21, 2016
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myelomaInger S Nijhof, Laurens E Franssen, Mark-David Levin, et al.
Journal of Clinical Immunology|May 20, 2023
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 PneumoniaQuentin Philippot, Arnaud Fekkar, Adrian Gervais, et al.
Haematologica|January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myelomaHenk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Circulation|November 11, 2016
Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective StudiesBakhtawar K Mahmoodi, Mary Cushman, Inger Anne Næss, et al.
Hypertension (Dallas, Tex. : 1979)|January 28, 2020
Influence of Age on Upper Arm Cuff Blood Pressure MeasurementDean S Picone, Martin G Schultz, Petr Otahal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.
Pageof 78